Stable expression of short-hairpin RNAs (shRNAs) directed against the X-linked inhibitor of apoptosis (XIAP) resulted in the generation of three MDA-MB-231 cell lines (XIAP shRNA cells) with reductions in XIAP mRNA and protein levels 485% relative to MDA-MB-231 cells stably transfected with the U6 RNA polymerase III promoter alone (U6 cells). This RNA interference (RNAi) approach dramatically sensitized these cells to killing by the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Importantly, loss of XIAP also sensitized the cells to killing by taxanes but had no additional effects on killing by carboplatin and doxorubicin. The increased sensitivity of the XIAP shRNA cells to killing by TRAIL and taxanes correlated with enhanced caspase cleavage and activation, including caspase-8, and robust processing of poly(ADP-ribose) polymerase and BID compared to U6 cells. Additionally, increasing XIAP levels by adenovirus-mediated expression protected both XIAP shRNA and U6 cells from TRAIL killing in a dose-dependent manner. The effects observed by stable RNAi with respect to TRAIL sensitization were also achieved following downregulation of XIAP in Panc-1 cells treated with a second-generation, mixed-backbone antisense oligonucleotide, AEG 35156/GEM640. These data indicate that reducing XIAP protein expression by either RNAi or antisense approaches increases cancer cell susceptibility to functionally diverse chemotherapeutic agents and supports the notion that downregulation of XIAP in vivo may synergize with disease-relevant chemotherapeutic regimes, including TRAIL and taxanes, to increase the effectiveness of antineoplastic agents.
Introduction
The ability to resist apoptosis is a hallmark of cancer, enabling cells to survive in a largely proapoptotic environment and overcome many of the cytotoxic effects of many standard chemotherapeutic agents (Reed, 2003) . A group of cysteine-dependent aspartate-specific proteases, the caspases (Alnemri et al., 1996) , carries out apoptosis by cleaving a broad range of cellular proteins, ultimately resulting in cell death (Shi, 2002) . Initiator caspases (caspase-2, -8, -9, -10), activated by their own proximity-induced proteolysis, in turn activate the so-called executioner caspases (caspase-3, -6, -7) that ultimately carry out apoptotic destruction of target proteins and the cell itself (Stennicke et al., 2002) . Members of both the Bcl-2 and the inhibitor of apoptosis (IAP) families are widely expressed in cancers (Tsujimoto et al., 1985; Weller et al., 1995; Ambrosini et al., 1997; Liston et al., 1997; LaCasse et al., 1998; Wagenknecht et al., 1999; Tamm et al., 2000) , and increasing evidence indicates they afford protection to cancer cells by controlling caspase activation. The antiapoptotic members of the Bcl-2 family, including Bcl-2 and Bcl-x L , act predominantly at the mitochondrial membrane to prevent caspase activation by interfering with the release of cytochrome c required for formation of a functional apoptosome complex involving apoptotic-activating factor 1 (Apaf1) and caspase-9 (Cory and Adams, 2002) . By contrast, the IAPs bind to and directly inhibit both initiator and executioner caspases, notably caspase-9, -7 and -3 Roy et al., 1997; Takahashi et al., 1998) . As such, IAPs provide a powerful line of defense to the cell from apoptotic stimuli, a circumstance exploited by some cancer cells to enhance their resistance to both environmental cues and therapeutic regimens that would normally trigger their demise.
To date, eight members of the human IAP family have been identified by virtue of a functional baculovirus IAP repeat (BIR) domain comprising approximately 80 amino acids (Liston et al., 2003) . Members of the IAP family include survivin, X-linked inhibitor of apoptosis (XIAP), cellular inhibitor of apoptosis (cIAP)-1 (also known as HIAP-2) and cIAP-2 (also known as HIAP-1). Survivin is unique to the IAP family because it functions prominently in cell division by controlling microtubule stability and assembly, while its role as a direct inhibitor of caspases remains unclear (Shin et al., 2001; Giodini et al., 2002) . By contrast, cIAP-1, cIAP-2 and XIAP act primarily as caspase inhibitors Roy et al., 1997) , indicating overlapping and perhaps necessary redundant functions to provide adequate protection from apoptosis during growth and development. Of the IAPs, XIAP is the most potent caspase inhibitor Roy et al., 1997; Holcik and Korneluk, 2001) , which has prompted detailed structure-function investigations of this protein leading to important advances in understanding XIAP regulation in both normal and cancer cells (Du et al., 2000; Verhagen et al., 2000; Chai et al., 2001; Huang et al., 2001; Liston et al., 2001; Riedl et al., 2001; Suzuki et al., 2001; Hegde et al., 2002; van Loo et al., 2002) . These studies have identified proteins such as XIAP-associated factor 1 (XAF1) (Liston et al., 2001) , second mitochondrial activator of caspases/direct IAP binding protein with low pI (Smac/DIABLO) (Du et al., 2000; Verhagen et al., 2000) , Omi/HtrA2 (Suzuki et al., 2001; Hegde et al., 2002; van Loo et al., 2002) and most recently GSPT1 (Hegde et al., 2003) that negatively regulate XIAP function and affect its stability within cells. This tight control over cellular XIAP activity demonstrates the importance of this protein in maintaining a proper apoptotic threshold within the cell.
Evidence is emerging that XIAP overexpression or deregulation contributes to the increased survival of various cancers. Rottlerin, a selective inhibitor of protein kinase C d, has been shown to enhance tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced killing in colon carcinoma cell lines (Tillman et al., 2003) . This enhanced killing correlated with a loss of XIAP (and cIAP-1) in the presence of the drug. By contrast, fibroblast growth factor 2-mediated upregulation of XIAP and cIAP-1 was found to protect small cell lung cancer cells from etoposide-induced cell death (Pardo et al., 2003) . Similarly, the resistance of melanoma cell lines to TRAIL-mediated apoptosis correlated with greater amounts of XIAP associated with active caspase-3 (Zhang et al., 2001) . Polyphenylurea compounds have also been shown to bind to the BIR2 region of XIAP (and perhaps other IAPs) and induce apoptosis in numerous cancer cells and increase the effectiveness of various chemotherapeutic regimens (Schimmer et al., 2004) .
Studies have also attempted to determine the effects of directly targeting XIAP knockdown on cell survival and cancer cell resistance to cytotoxic agents. Adenovirus-mediated expression of antisense XIAP resulted in significant loss of XIAP protein and sensitization of ovarian cancer cell lines to cisplatin-induced apoptosis (Sasaki et al., 2000) . The use of first-generation phosphorothioate antisense oligonucleotides (ASOs) against XIAP was shown to significantly reduce XIAP protein levels in T24 bladder cancer cells and to sensitize the cells to killing by adriamycin (Bilim et al., 2003) . We have also utilized ASOs against XIAP and illustrated that targeted downregulation of XIAP increased the potency of different chemotherapeutics in killing the non-small-cell lung cancer cell line H460 in vitro (Hu et al., 2003) . In the same study, we demonstrated that repeated delivery of XIAP ASOs systemically to SCID/ RAG2 mice reduced the size of H460 xenograft tumors and acted in combination with conventional chemotherapeutics (Hu et al., 2003) . Most recently, XIAP-null colorectal carcinoma cells were generated and had increased sensitivity to TRAIL killing (Cummins et al., 2004) .
To date, most XIAP knockdown studies have assessed the effects of transient XIAP downregulation on cellular phenotypes. Here, we extend our studies on the effects of XIAP downregulation on cancer cell survival by generating MDA-MB-231 breast carcinoma cell lines with stable downregulation of XIAP by RNA interference (RNAi). This was accomplished by selecting for stable clones following transfections with a vector containing a neomycin-resistant marker and carrying a potent short-hairpin RNA (shRNA) sequence directed against XIAP. Three independent cell lines isolated had between 85 and 95% reductions in XIAP at the mRNA and protein levels, which allows a study of the effects of chronic XIAP loss on breast cancer cells in the absence of the complications associated with transient and variable XIAP inhibition and without the use of transfection agents or adenoviral vectors that introduce clear but ill-defined stresses to cells. We report that XIAP is an important survival factor for MDA-MB-231 cells in resistance to some, but not all, chemotherapeutics. The results provide new insights into the effects of XIAP loss on breast cancer cell survival and the context in which XIAP downregulation may prove most successful therapeutically.
Results

Stable downregulation of XIAP in MDA-MB-231 cells
Of the many XIAP shRNA-treated MDA-MB-231 clones isolated and assessed, three lines referred to as X-G4, X-A4 and X-H3 had greater than 85% reductions of XIAP mRNA relative to an MDA-MB-231 clone stably transfected with a construct containing the U6 promoter alone (U6-E1) (Figure 1a) . The U6-E1 line is representative of many control MDA-MB-231 cells screened in which XIAP protein levels varied less than two-fold from that found in the MDA-MB-231 parental nontransfected cells (Figure 3 ). The loss of XIAP mRNA correlated directly with dramatic 85-95% reductions in XIAP protein (Figure 1b ) in the X-G4, X-A4 and X-H3 cell lines relative to U6-E1. Western blot analysis indicated that the loss of XIAP protein in these cells was maintained for successive generations (Figure 1b) .
No compensation of other IAP and Bcl-2 members upon loss of XIAP RNase protection assays were performed to determine if compensatory changes in the relative mRNA levels of other IAPs (Figure 2a ) and Bcl-2 (Figure 2b ) family members occurred in response to the stable downregulation of XIAP. Other than the absence of XIAP, no significant changes in other IAP or Bcl-2 mRNA levels (normalized to GAPDH and L32 by phosphorimager analysis) were observed in the X-G4, X-A4 and X-H3 cell lines relative to U6-E1. Consistent with these findings, Western blot analysis (Figure 2c) shows that protein levels of cIAP-1, cIAP-2 and survivin in the IAP family and Bcl-xL (highly expressed) of the Bcl-2 family remain unchanged in the three XIAP shRNA cell lines relative to control U6-E1 cells.
An interferon response is not induced by XIAP shRNA expression
Recent reports reveal that a potential limitation of RNAi is its ability to induce an interferon response in some cells (Bridge et al., 2003; Sledz et al., 2003) . Due to the known actions of interferons on cellular function (i.e. inducing apoptosis), such an event would significantly complicate attribution of RNAi effects on XIAP knockdown alone (Bridge et al., 2003; Sledz et al., 2003) . The levels of signal transducer and activator of transcription 1 (STAT1) and 2 0 ,5 0 -oligoadenylate Figure 2 No compensation in other IAP and Bcl-2 family members in the XIAP shRNA MDA-MB-231 cells. RNase protection assays were carried out as described in Materials and methods to analyse the relative mRNA levels of the IAP and Bcl-2 family members in the XIAP shRNA cell lines compared to U6-E1.
(a) The hAPO-5c template probe set was used to compare IAP levels. No difference, other than a loss in XIAP, was detected in the XIAP shRNA cell lines X-G4, X-A4 and X-H3 when compared to U6-E1. (b) Similarly, no differences in the mRNA levels of the Bcl-2 family members were observed as determined with the hAPO-2b template set and phosphorimager analysis. (c) Western blot analysis confirms the RNase protection assay and shows that there are no significant differences in the cell lines between the protein levels of Bcl-xL and the three other major IAP family members survivin, cIAP-1 and cIAP-2 Figure 5 ). While there were only small differences in X-G4 and U6-E1 propidium iodide (PI)-positive cells in the absence of TRAIL, a dramatic increase in PI-positive cells and loss of adherence were observed for X-G4 but not U6-E1 cells subjected to TRAIL ( Figure 5 ).
XIAP suppression enhances TRAIL-induced cleavage of caspases and processing of BID and PARP
Western blot analysis was performed on the MDA-MB-231 cell lines to assess the effect of XIAP suppression on cleavage of caspases, BID and poly(ADP-ribose) polymerase (PARP) in the absence and presence of TRAIL ( Figure 6 ). Time courses were performed (1, 2, 4, 7 and 24 h) with optimal processing after 7 h as shown. Without TRAIL, no significant caspase cleavage was detectable in either X-G4 (lane 3) or U6-E1 (lane 1) cells. By contrast, TRAIL addition (10 ng/ml for 7 h) promoted the conversion of procaspase-3, -7 and -9 to their respective and presumably active forms in both Cell viability was determined by the WST-1 assay as described in Materials and methods. The three XIAP shRNA cell lines exhibit similar kill curves in response to dosing with different TRAIL concentrations. By contrast, the U6-E1 XIAP-expressing cell line is much more resistant to TRAIL killing and requires an approximately two-logs greater concentration for its cell viability to be reduced by 50% (IC 50 ). The X-G4 cell line (m), which displays the greatest reduction in XIAP protein and mRNA, is the most sensitive of the three shRNA cell lines to TRAIL killing, particularly at the lower TRAIL concentrations. Statistically significant differences in survival of the XIAP shRNA cells compared to U6-E1 were determined by a one-way ANOVA using the Dunnett multiple comparisons test (*Po0.001)
cells, but the extent of processing was much more robust in X-G4 cells (lane 4) relative to U6-E1 cells (lane 2).
There was also substantially more BID processing and greater activation of caspase-8 in the presence of TRAIL. This corresponded to complete PARP cleavage in X-G4 cells compared to much less TRAIL-induced cleavage of PARP (E30%) in U6-E1 cells.
Adenovirus-mediated expression of XIAP restores TRAIL resistance
Both U6-E1 and X-G4 cells were infected at the indicated multiplicities of infections (m.o.i.s) of plaque forming units per cell (PFU/cell) with either a lacZ recombinant adenovirus (lacZ.Ad5) or XIAP recombinant adenovirus (XIAP.Ad5). XIAP protein levels in noninfected U6-E1 cells were set to 100%. XIAP levels in lacZ.Ad5-infected U6-E1 cells were no different from that observed in uninfected cells (data not shown). Cellular expression of XIAP (normalized to GAPDH) was determined 48 h postinfection with XIAP.Ad5. As shown in Figure Increasing XIAP levels in U6-E1 cells at this adenovirus dose further enhanced its resistance to TRAIL killing relative to lacZ.A5-infected cells. When XIAP was overexpressed, both U6-E1 and X-G4 cells became highly resistant to TRAIL killing relative to lacZ.Ad5-infected controls (Figure 7c ). Statistically significant differences in survival of X-G4 (both lacZ.Ad5 and XIAP.Ad5 infected) and XIAP.Ad5-infected U6-E1 cells compared to the lacZ.Ad5-infected U6-E1 cells are indicated (*Po0.001).
XIAP shRNA cells are more sensitive to killing by cytotoxic agents
Studies were carried out to determine the effect of stably downregulated XIAP on sensitizing MDA-MB-231 cells to killing by different clinically relevant chemotherapeutic agents. X-G4, X-A4 and X-H3 XIAP shRNA cells were all more sensitive to killing by docetaxel in the absence (Figure 8a ) or presence ( Figure 8b ) of a fixed dose of vinorelbine. Similar results were obtained with paclitaxel (not shown). By contrast, no differences in the killing of U6-E1 and the three XIAP shRNA cell lines (X-G4, X-A4 and X-H3) by carboplatin ( Figure 8c ) and doxorubicin ( Figure 8d ) were noted. Values for the XIAP shRNA cells that are statistically significant from U6-E1 cells are indicated (*Po0.001).
Differential caspase activation by TRAIL and chemotherapeutics
Caspase-3 and -9 activities in cytoplasmic extracts prepared from untreated U6-E1 and X-G4 cells or following treatment with either TRAIL, docetaxel plus vinorelbine, or carboplatin were measured by monitoring cleavage of DEVD-AFC and LEHD-AFC, respectively. No detectable caspase-3 or -9 activities were 
Discussion
This is the first report, to our knowledge, that has addressed the effects of stable downregulation of XIAP by shRNAs on cancer cell survival. This stable RNAi approach has advantages over studies utilizing synthetic short interfering RNAs (siRNAs) or plasmids and viruses that express shRNAs due to the transient nature of targeted gene inactivation by these methods. Additionally, the use of liposomal transfection reagents or viruses in many cases imparts stress to the cell, which can alter and complicate the cellular response to target knockdown (Dykxhoorn et al., 2003) , particularly in the context of apoptosis induction. The stable downregulation of XIAP protein therefore allows experiments to be carried out over longer time courses and in the absence of such complications, which is necessary for obtaining a clearer understanding of how XIAP suppression enhances apoptosis of these estrogen-independent breast cancer cells. Importantly, the reduction of XIAP between 85 and 95% in the three XIAP shRNA MDA-MB-231 cell lines (X-G4, X-A4 and X-H3) occurs with no compensatory changes in the levels of other IAP or Bcl-2 family members ( Figure 2 ) and without induction of a potentially complicating interferon response (Figure 3) . These findings help ensure that it is the loss of XIAP rather than nonspecific effects of shRNA expression that sensitizes the breast cancer cells to killing by TRAIL and taxanes. Such complications have been observed previously whereby stable downregulation of Bcl-xL by an antisense approach led to dramatic increases in cIAP-1, Figure 6 Biochemical analysis of cleavage of caspases and processing of BID and PARP in the U6-E1 and X-G4 MDA-MB-231 cells treated with or without TRAIL (10 ng/ml) was performed by Western blot analysis with the 7 h time point shown. Little or no caspase activation, PARP cleavage or BID processing is detectable in either the U6-E1 or X-G4 cells in the absence of TRAIL (lanes 1 and 3, respectively) . TRAIL induces a dramatic conversion of both initiator and executioner caspases from their pro-to active forms and substantial PARP and BID processing in the X-G4 cell line (lane 4). By contrast, there is significantly less PARP cleavage, BID processing and caspase activation in TRAILtreated U6-E1 cells (lane 2) which imparted an unexpected survival advantage to in DU145 prostate cancer cells when treated with various chemotherapeutic agents (Vilenchik et al., 2002) .
There has been less focus on the roles of IAPs in cancers compared to the antiapoptotic Bcl-2 family members Bcl-2 and Bcl-xL (Liston et al., 2003) . Furthermore, MDA-MB-231 cells express relatively high levels of Bcl-xL (Figure 2) (Hsu et al., 1997) and therefore provide an interesting background in which to study the loss of XIAP on cancer cell survival. Notably, under standard culture conditions and in the absence of externally applied apoptotic triggers, suppression of XIAP expression did not induce cleavage (Figure 6 ) or activation of caspases (Figure 9 ). Therefore, for MDA-MB-231 cells grown in culture, it appears that an apoptotic trigger such as treatment with TRAIL and taxanes (see below) is required for meaningful caspase activation and cell death even when XIAP is suppressed. These findings differ somewhat from a recent study in which MDA-MB-231 cells expressing XAF1 following adenovirus-mediated infection had enhanced caspase-3 activation and cell death in the absence of any apparent apoptotic mediator (Yang et al., 2003) . In this example, it is likely that multiple stresses arising from protracted adenovirus infection, as well as XIAP-related and nonrelated effects of XAF1, collectively induced caspase-dependent cell death. Our findings also vary from a report showing that polyphenylurea compounds, which target the BIR2 domain of XIAP and interfere with its ability to suppress caspase-3, could induce death of cancer cells on their own (Schimmer et al., 2004) . However, as pointed out in that study, these compounds may target other IAPs. Therefore, suppression of multiple IAPs and/or non-IAP-related effects of these drugs might be responsible for triggering apoptosis of cancer cells.
The dramatic sensitization of X-G4 cells to TRAIL killing compared to U6-E1 cells correlated not only with enhanced cleavage (Figure 6 ) and activation (Figure 9 ) of caspase-3 and -9 but also resulted in substantial caspase-8 cleavage and processing of BID ( Figure 6 ). Since XIAP does not bind to and directly regulate caspase-8 , the increased levels of active caspase-9 and -3 in the absence of XIAP likely work in a feed forward manner to further process procaspase-8 leading to greater BID cleavage. This hypothesis is in agreement with a recent study demonstrating that caspase-3 is an integral component of the death-inducing signaling complex (DISC) and required for optimal caspase-8 activation (Aouad et al., 2004) . Therefore, the loss of XIAP would be expected to enhance caspase-3 processing of caspase-8 in response to TRAIL treatment, which is consistent with our results. By contrast, even though Cummins et al. (2004) show that loss of XIAP sensitizes colon carcinoma cells to TRAIL killing they did not observe changes in processing of caspase-9 or -8 compared to wild-type cells. However, no caspase-9 activity assays were performed in that study, so they could not rule out the possibility that there were no differences in activation of this enzyme between wild-type and XIAP-null cells. Furthermore, our data agree with Borden and co-workers who demonstrated that transient siRNA downregulation of XIAP resulted in increased activation of not only caspase-3 but also caspase-8 and -9 in response to TRAIL (Chawla-Sarkar et al., 2004) . Additionally, we also show that adenovirus-mediated expression of XIAP in both X-G4 and U6-E1 cells protects these cells from TRAIL killing in a dose-dependent manner and normalizing XIAP levels in X-G4 cells reverses sensitization to TRAIL killing (Figure 7 ). This unequivocally demonstrates that the loss XIAP rather than off-target effects of shRNA expression is responsible for enhanced TRAIL killing of these breast cancer cells.
The results we and others have observed with respect to loss of XIAP on TRAIL sensitization, while potentially important, may be less relevant from a clinical perspective given that TRAIL is not yet approved for use in the clinic and may have associated cytotoxicity issues (reviewed in Shi et al., 2003) . In this regard, the stable loss of XIAP by RNAi is most useful when addressing the role of this IAP in protecting cancer cells from killing by more conventional chemotherapeutics (Figure 8) . Furthermore, the requirement for protracted treatment with many of these drugs makes it much more efficient and reliable to perform such studies by stable RNAi downregulation compared to transient siRNA or antisense approaches. We find that loss of XIAP increases the effectiveness of some, but not all, conventional chemotherapeutics in killing MDA-MB-231 cells (Figure 8 ). The sensitivity of X-G4 cells to taxanes in the absence (Figure 8a ) or presence of a fixed dose of vinorelbine (Figure 8b ) corresponds to greater caspase-3 activity in these cells (Figure 9c ). Of note, paclitaxel-mediated death of BJAB cells has been found to proceed through a receptor-independent activation of caspase-3, followed by caspase-3-mediated activation of caspase-8 (von Haefen et al., 2003) . If this mechanism is generally applicable, then XIAP rather than Bcl-2 or Bcl-xL suppression would be more likely to synergize with taxanes such as docetaxel in killing cancer cells since it would be less dependent on the intrinsic mitochondrial death pathway. Therefore, as a consequence of greater caspase activation in the absence of XIAP (Figure 9c ), there is a much lower apoptotic threshold required for killing these cells by taxanes. In agreement, XIAP overexpression has been shown to protect LNCaP prostate cells from paclitaxel-induced apoptosis (Nomura et al., 2003) .
The failure of XIAP downregulation in MDA-MB-231 cells to synergize with carboplatin ( Figure 8c ) and doxorubicin (Figure 8d ) is interesting and may be related to a number of factors. First, a recent study has identified that a significant portion of cisplatininduced killing in four different cancer cell lines likely occurs by caspase-independent mechanisms (Cummings et al., 2004) . Doxorubicin killing of acute myelogenous leukemia (AML) cells has also been shown to have a caspase-independent component (Carter et al., 2003) , and similar to our findings was not dependent on XIAP levels. Furthermore, although we initially observed increased caspase-3 activity in X-G4 cells compared to U6-E1 cells 40 h following carboplatin and doxorubicin treatment (not shown), we found similar caspase-3 activities by 72 h in both cell lines following carboplatin treatment (Figure 9d ), which further helps explain the lack of a protective effect of XIAP with protracted treatment of these drugs.
The generation of the XIAP shRNA MDA-MB-231 cells in this study is an extension of our current efforts to downregulate XIAP in vivo, through the use of a secondgeneration XIAP ASO, named AEG 35156/GEM640, and in the process determine where XIAP downregulation is likely to be most beneficial in combination with standard chemotherapies. The above results suggest that downregulating XIAP is likely to act synergistically with docetaxel or paclitaxel (with or without vinorelbine) in vivo. This analysis holds true as we find that the combined use of AEG 35156/GEM640 with docetaxel results in significant regression of human prostate PC-3 tumor xenografts in nude mice when compared with treatment of docetaxel and a scrambled control oligonucleotide (EC LaCasse, ER Kandimalla, S Agrawal and JP Durkin, manuscript in preparation). The effect of XIAP loss in sensitizing the MDA-MB-231 cells to Figure 9 Effect of chemotherapies on caspase activities in X-G4 and U6-E1 MDA-MB-231 cells. Caspase-3 (DEVD-AFC) or caspase-9 (LEHD-AFC) activities in cytoplasmic extracts prepared from untreated or treated X-G4 or U6-E1 cells were carried out as described in Materials and methods. (a) There is much greater caspase-3 induction by TRAIL (10 ng/ml for 4 h) in X-G4 (m) compared to U6-E1 (*) cells and no activity in the untreated cells (J,n). (b) Similar to caspase-3, there is greater TRAIL-induced caspase-9 activity in X-G4 (m) compared to U6-E1 (*) cells. (c) A 72 h treatment with combined docetaxel (2 nM) and vinorelbine (1.5 nM) induces heightened caspase-3 activity in X-G4 cells (m) versus U6-E1 (*) cells. (d) By contrast, 72 h carboplatin (400 mM) treatment does not result in differences in caspase-3 activities between U6-E1 (*) and X-G4 cells (m) TRAIL killing also prompted us to address the effect of XIAP ASOs on TRAIL-mediated killing of Panc-1 cells (Figure 10 ). The pancreatic cancer cells were used in this study because they efficiently take up the ASOs and have relatively high levels of XIAP protein expression. This complimentary approach to the stable RNAi provides further and independent evidence that XIAP is a key antiapoptotic protein in protecting cancer cells from TRAIL-mediated killing.
In summary, the ability to selectively downregulate XIAP by stable RNAi and antisense approaches has enabled us to highlight the importance of this IAP in resistance to chemotherapy-induced cell death. The sensitization effects of XIAP suppression with TRAIL are not restricted to long-term inhibition of protein expression in culture, and similar results were achieved with both stable RNAi and transient ASO approaches. However, stable suppression of XIAP was required to demonstrate that suppression of this IAP acts synergistically with protracted treatment (470 h) of microtubule-interfering drugs to enhance the killing of MDA-MB-231 breast cancer cells (Figure 8 ). These changes occurred despite high expression levels of Bcl-xL (Figure 2 ). We also demonstrate for the first time that loss of XIAP does not necessarily synergize with all chemotherapeutics in killing cancer cells. Future work with these cells will be useful to investigate the mechanisms of actions of various chemotherapeutics with regard to caspase-dependent and caspase-independent killing mechanisms and whether or not overexpression of other IAPs and Bcl-2 family members Bcl-2 and Bcl-xL can compensate for the loss of XIAP. Together, these findings will be useful to help guide where XIAP antisense therapy (AEG 35156/GEM640), which is currently undergoing Phase I clinical trials, will be most beneficial as a cancer therapeutic.
Materials and methods
Reagents, antibodies and cell lines
All materials were of reagent grade or better unless otherwise stated. RIAP-3 and RIAP-1 are polyclonal anti-XIAP and anti-cIAP-1/2 antibodies, respectively, and were generated in the laboratory as described previously (Holcik et al., 2002) . The anti-caspase-3 polyclonal antibody (CPP32) was from Sigma (St Louis, MO, USA), the anti-caspase-9 monoclonal antibody (MAB8301) was from R&D Systems (Minneapolis, MN, USA), the anti-caspase-8 monoclonal antibody (AHZ6502) was from BioSource International (Camarillo, CA, USA), the anti-caspase-7 (#9492), anti-PARP (#9542), anti-BID (#2002) and anti-Bcl-xL (#2762) polyclonal antibodies were from Cell Signaling Technologys (Beverly, MA, USA), the anti-STAT1 monoclonal antibody (sc-464) was purchased from Santa Cruz Biotechnologys (Santa Cruz, CA, USA), the polyclonal anti-survivin antibody (SURV11-A) was from Alpha Diagnostic International (San Antonio, TX, USA) and the anti-GAPDH monoclonal antibody (RGM2) was from Advance Immunochemical Inc. (Long Beach, CA, USA). The TOPO-TAs cloning kit, Taq polymerase, shRNA primers and the Lipofectamine 2000s transfection reagent were obtained from Invitrogent Life Technologies (Burlington, ON, Canada). XL-10 Gold competent bacteria and the pfuTurbos polymerase were purchased from Stratagene (La Jolla, CA, USA). The estrogen-independent breast cancer cell line MDA-MB-231 and the pancreatic cancer cell line Panc-1 were from the American Type Culture Collection (ATCC, Manassas, VA, USA). The cell proliferation reagent WST-1 was purchased from Roche Diagnostics (Laval, QC, Canada). The BD RiboQuants Multi-probe RNase Protection Assay system and the hAPO-5c and hAPO-2b multiprobe template sets were bought from BD Biosciences (Mississauga, ON, Canada). The ECL Plus chemiluminescent reagent, [a- 32 P]UTP and Hyperfilmt were from Amersham Biosciences (Baie d'Urfe´, QC, Canada). RPMI and DMEM culture media were from Wisent (St Bruno, QC, Canada), and FBS and geneticins (G418) were from Invitrogen Gibco BRLt (Burlington, ON, Canada). Recombinant human TRAIL was obtained from R&D Systems (Minneapolis, MN, USA) . Primers for TaqMans analysis were purchased from either Qiagen (Mississauga, ON, Canada) or Integrated DNA Technologies (Coralville, IA, USA). Carboplatin, paclitaxel and doxorubicin were purchased from Sigma. Docetaxel (Aventis) and vinorelbine (Glaxo Wellcome Inc.) were purchased from the manufacturers. Ac-DEVD-AFC and Ac-LEHD-AFC were purchased from BioMol Research Laboratories Inc. (Plymouth Meeting, PA, USA).
XIAP shRNA plasmid constructs and screening
Primers for shRNAs against XIAP were selected based on the shagging-PCR protocol as described previously (Paddison et al., 2002) . PCR amplification of the human RNA polymerase III U6 promoter was carried out by pfuTurbos polymerase with a forward U6 primer (5 0 -AGG AGA TCT GCG CAG GCA AAA CGC ACC AC-3 0 ) containing a BglII site (bold) and the 96-nucleotide shRNA XIAP primers (containing the 21 bp complement of the 3 0 -end of the U6 promoter). The PCR products were incubated for 10 min (721C) with Taq polymerase and the E430 bp U6-XIAP shRNA sequences (five in total) were cloned into the pCRs2.1-TOPOs vector by the TOPO-TA cloning protocol (Invitrogen). Following sequencing of individual clones, the ability of each of the five XIAP shRNA constructs to suppress XIAP mRNA levels was measured by quantitative RT-PCR (TaqMans analysis -see below). Briefly, HeLa cells were transiently transfected with the XIAP shRNA TOPO-TAs vectors using Lipofectamine 2000s, and 24 h post-transfection total RNA was prepared for TaqMan analysis. Two of the five shRNA constructs significantly lowered XIAP mRNA (60-80%) given transfections efficiencies between 70 and 90%. Suppression of XIAP protein by the two effective shRNA constructs was demonstrated by Western blot analysis (see below) 48 h after transfection of HeLa cells. The two shRNA plasmids reduced XIAP protein transiently by 70 and 80%, respectively, and could each sensitize the cells to TRAIL killing (not shown).
Generation of stable XIAP shRNA MDA-MB-231 cells
The most effective construct from the transient transfections was used to produce MDA-MB-231 cells stably expressing the XIAP shRNA sequence. The shRNA sequence targets an extreme C-terminal coding region of XIAP (5 0 -AAG TGT CCC ATG TGC TAC ACA GTC ATT AC-3 0 ). A pCDNA3 vector devoid of the CMV promoter sequence (pCDNA3 CMVÀ) was generated by double BglII/BamHI digestions and re-ligation. The U6-XIAP shRNA was cloned into the EcoRI site of pCDNA3 CMVÀ (XIAP shRNA construct). As a control, pCDNA3 CMVÀ containing only the human U6 promoter was also generated. Each of the XIAP shRNA or U6-only pCDNA3 CMVÀ vectors was linearized with BglII and transfected into MDA-MB-231 cells with the Lipofectamine 2000. At 24 h after the initial transfections, the cells were trypsinized and seeded in RPMI medium (10% FBS) containing 600 mg/ml geneticins (G418). Individual cell clones were picked (15 in total), amplified and then screened by Western blot analysis (see below) for XIAP protein levels. Three independent XIAP shRNA MDA-MB-231 clones were selected based on drastically reduced XIAP mRNA and protein levels (485%).
Western blot analysis
MDA-MB-231 and Panc-1 cells were grown in six-well plates at densities in the range of 5-8 Â 10 5 cells/well in RPMI medium with 10% FBS and 600 mg/ml G418 and DMEM with 10% FBS, respectively. Cells were either untreated, treated with TRAIL (1-10 ng/ml) or INF-b (200 U/ml) where indicated for various times. At the stated end points, the cells were scraped from the culture dishes and mixed in a 1 : 1 ratio with phosphate-buffered saline (PBS, pH 7.2) containing protease inhibitors PMSF (1 mM), leupeptin (1 mg/ml) and aprotinin (1 mg/ml). The cells were harvested by centrifugation (41C), lysed with RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM NaF, 1 mM vanadate, 1% NP-40, 0.25% sodium deoxycholate, 1 mM PMSF, 1 mg/ml leupeptin and 1 mg/ml aprotinin -protease inhibitors added fresh) for 45 min with mixing at 41C and the lysate was clarified by centrifugation at 10 000 g (15 min at 41C). Protein concentrations were determined with the Bradford assay (Bio-Rad) and diluted to a final concentration of 1 mg/ml in SDS sample buffer. Proteins resolved by SDS-PAGE (7.5, 10.0 or 12.5%) were transferred to PVDF membranes using a Semi-dry transfer apparatus (Hoefer SemiPhor). All membranes were incubated with blocking solution (5% skim milk in TBS containing 0.1% Tween 20) for 1 h at room temperature. The membranes were subsequently incubated with primary antibodies in blocking solution overnight (at 41C) or for 2 h at room temperature. The proteins were visualized by chemiluminescence (ECL Plus -Amersham Biosciences) following incubation with either commercially available (Amersham Biosciences) horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgGs for 1 h (1 : 2000-1 : 5000 dilutions) in blocking solution. Densitometry was performed with Scion Image s (NIH freeware) where indicated and values were normalized to GAPDH.
Quantitative RT-PCR
Endogenous XIAP and OAS1 mRNA levels in untreated and INF-b-treated parental, U6 control or XIAP shRNA MDA-MB-231 cell lines were measured using quantitative RT-PCR as per the TaqMan method (Heid et al., 1996; Lo et al., 1999) . The primer sets used for XIAP amplification were 5 0 -GGT GAT AAA GTA AAG TGC TTT CAC TGT-3 0 and 5 0 -TCA GTA GTT CTT ACC AGA CAC TCC TCA A-3 0 . The primer sets for OAS1 amplification were 5 0 -AGG TGG TAA AGG GTG GCT CC-3 0 and 5 0 -ACA ACC AGG TCA GCG TCA GAT-3 0 , as described previously (Bridge et al., 2003) . The sequence of the TaqMan probes for XIAP and OAS1 were 5 0 -(FAM)-CAA CAT GCT AAA TGG TAT CCA GGG TGC AAA TAT C (TAMRA)-3 0 and 5 0 -(FAM) CAG GCA AGG GCA CCA CCC TCA (TAMRA)-3 0 , respectively. Total RNA was isolated using RNeasy mini-spin columns combined with DNase I treatment (Qiagen). A 25-100 ng portion of total RNA was used for the analysis. The RNA was reversetranscribed and PCR-amplified using the TaqMan EZ RT-PCR kit (PE Applied Biosystems, Foster City, CA, USA). All the RT-PCR steps were performed on an ABI Prism 7700 Sequence Detector and quantified using the cycle threshold (Ct) method, and normalized to GAPDH mRNA using PE-ABI supplied primers and probe (JOE-labeled). Primers and probes were used at concentrations of 600 and 200 nM, respectively. The thermal cycling conditions for the RT step were 501C for 2 min, 601C for 30 min and 951C for 5 min followed by 45 PCR cycles at 941C for 20 s and 601C for 1 min per cycle.
RNase protection assays
Five million MDA-MB-231 cells were seeded in 100 mM dishes and total RNA was prepared 24 h later with the RNeasy kit (Qiagen). The relative mRNA levels of the IAP and Bcl-2 family members in the MDA-MB-231 cell lines were determined using the Riboquants Multiprobe RNase protection assay with the hAPO-5c and hAPO-2b multiprobe template sets as per the manufacturer's instructions. The mRNA levels were analysed by phosphorimager analysis (Molecular Dynamics Storm 860 -Image Quant v4.2 software) and normalized to either GAPDH or L32.
Antisense downregulation of XIAP in Panc-1 cells
Panc-1 cells were treated with a 19-mer second-generation mixed-backbone XIAP ASO, named AEG 35156/GEM640, or a 19-mer scrambled control oligonucleotide designated as AEG 35187, synthesized according to methods previously described (Agrawal et al., 1997) . Briefly, Panc-1 cells were seeded in either 96-well (for cell viability studies) or six-well plates (for Western blot analysis) at the respective densities of 2.5 Â 10 4 and 8 Â 10 5 cells/well. At 24 h after seeding, the cells were transfected (5 h) with 100 nM of either AEG 35156/ GEM640 or AEG 35187 using Lipofectamine 2000 according to the manufacturer's instructions (Invitrogen). Medium was changed overnight, and the following day the cells were subjected to a second round of transfections as above prior to performing the cell viability studies or Western blot analysis.
Cell viability studies
MDA-MB-231 and Panc-1 cells were seeded in 96-well plates at densities of 2.0 Â 10 4 and 2.5 Â 10 4 cells/well, respectively. Where indicated, MDA-MB-231 cells were also seeded at densities of 1.5 Â 10 4 cells/well and the following day infected with either the XIAP or lacZ adenoviruses, as described previously (Simons et al., 1999) , at an m.o.i. of 25-100 PFU/ cell. Either 24 h after seeding, 24 h after the recombinant adenovirus infections or after the second round of transfections of Panc-1 cells with either the XIAP ASO, AEG 35156/ GEM640 or AEG 35187 scrambled control oligonucleotide, drugs were added to the Panc-1 and MDA-MB-231 cells at the indicated doses and for varying durations. TRAIL was added to cells at different concentrations and cell viability was measured 18-20 h later by the WST-1 assay. For experiments with docetaxel and paclitaxel (with or without vinorelbine), carboplatin and doxorubicin, cells were treated for 72 h with different concentrations (as detailed within) prior to determining cell viability. At the given end points, cells were incubated at 371C for 2-7 h following the addition of the WST-1 reagent (10 ml) per well and the absorbance at 450 nm was measured and compared to cells treated without drugs. All experiments were performed at least three times with triplicate measurements at each drug concentration per experiment.
Propidium iodide staining
U6 and XIAP shRNA MDA-MB-231 cells grown in six-well plates were treated with PI (10 mg/ml) to assess late apoptotic death. Qualitative analysis of apoptotic cells (positive for PI staining) was performed and morphological changes in the presence and absence of TRAIL (7 h) were noted and correlated to the cell viability assays.
Processing of caspases, BID and PARP
Processing of caspases, BID and PARP cleavage in the MDA-MB-231 and Panc-1 cells in the absence and presence of TRAIL (1-10 ng/ml) was assessed by Western blot analysis as described using antibodies that detect both pro-(zymogen) and cleaved caspases and full-length and cleaved forms of BID and PARP. The conversions from pro-to processed caspases and BID and PARP cleavage were determined by densitometry as described and normalized to GAPDH levels.
Cell-free caspase assays
Cytoplasmic S-100 fractions and fluorogenic caspase assays were performed as described previously (Yang et al., 1997) . Briefly, X-G4 or U6-E1 cells were either untreated or incubated with TRAIL, docetaxel and vinorelbine, carboplatin or doxorubicin at the given concentrations and for the indicated length of times. A 30 mg portion of cytoplasmic extracts was incubated with either DEVD-AFC or LEHD-AFC (final concentration ¼ 30 mM) at 371C and release of free AFC was measured with excitation and emission wavelengths of 400 and 490 nm, respectively. The kinetics of free AFC release was measured over 2 h.
Statistical analysis
Statistical analysis was performed with either a one-way analysis of variance (ANOVA) using the Dunnett multiple comparisons test or an unpaired two-tailed t-test as indicated. A value of Po0.05 was considered to be statistically significant.
